Yaral To Expand Burgeoning Generics Portfolio With Support From Eversana
Industry Newcomer Poised For Three Additional Commercial Launches This Year
Executive Summary
With three additional commercial launches lined up for 2023, Yaral has opted to expand its pre-existing partnership with life sciences service provider Eversana to support these activities.
You may also be interested in...
‘Leading’ Swiss Fertility Firm Launches US Authorized Generics Unit
With a mission to provide access “to high quality, affordable, authorized generics and complex generic medicines to enhance healthcare outcomes,” Yaral Pharma has launched in the US.
Amneal Outlines Ambitions To Become Leading Affordable Medicines Supplier In US
While it currently sits in fourth place, Amneal’s co-CEO Chirag Patel has laid out ambitions for the firm to become the number one supplier of affordable medicines in the US.
Insitro’s Daphne Koller On The Marriage Of Biology And Machine Learning At The Company’s Heart
Industry veteran and serial entrepreneur Daphne Koller tells In Vivo about how her company, Insitro, is unleashing the potential of computational biology and machine learning to discover new drug compounds.